Why Clinuvel Pharmaceuticals (ASX:CUV) Is Up 5.9% After Strong Earnings and NASDAQ ADR Expansion Plans – And What’s Next

Clinuvel Pharmaceuticals recently reported full-year revenue of A$105.3 million and net income of A$36.17 million, declared its eighth consecutive annual dividend of A$0.05 per share, and affirmed plans for a Level II ADR listing on NASDAQ to boost U.S. investor visibility. This combination of consistent financial performance and expansion into the U.S. market signals continued…

Read More